Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adventrx phase IIb cancer trial gets review board OK
The phase IIb clinical trial is a multi-center, randomized study to evaluate the safety and efficacy of infusional CoFactor and 5-FU versus infusional leucovorin and 5-FU in subjects
The phase IIb clinical trial is a multi-center, randomized study to evaluate the safety and efficacy of infusional CoFactor and 5-FU versus infusional leucovorin and 5-FU in subjects
The studies, presented at the International Society for Human and Animal Mycology meeting in Paris, show that BAL8557 had no significant impact on the pharmacokinetics of ciclosporin and
The new data were presented at the 15th International HIV Drug Resistance Workshop in Sitges, Spain. The correlation of certain Fuzeon resistance mutations with the observed increases in
In addition, use of the compound was statistically superior in producing pain-free rates as early as 30 minutes, and significantly more patients reached pain-free status at two hours;
Pfizer Consumer Healthcare's global business of personal care and over-the-counter (OTC) products achieved sales of $3.9 billion in 2005 and includes market-leading brands such as Listerine, Nicorette, Sudafed
The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and
The agreement includes Metabolex's two clinical compounds, metaglidasen and MBX-2044, and additional follow-on compounds for which Ortho-McNeil, a Johnson & Johnson company, has received an exclusive license for
Having obtained positive results with Anturol, an oxybutynin gel product, in a phase II clinical study, Antares now plans to initiate a phase III clinical program in patients
The companies have not disclosed details of the specific compounds involved in the supply but have said that sales of the products exceeded $130 million in 2005. Lannett,
The T315I point mutation is attracting significant attention globally as T315I expressing cells are resistant to Novartis’ tyrosine kinase inhibitor, Gleevec, meaning chronic myeloid leukemia (CML) patients who